Study on NDUFB6 Gene and Its Potential as A Drug Target Or Biomarker

Target Name: NDUFB6

NCBI ID: G4712

NDUFB6

Study on NDUFB6 Gene and Its Potential as A Drug Target Or Biomarker

NDUFB6, or NADH:ubiquinone oxidoreductase subunit B6, is a protein that plays a crucial role in the metabolism of nicotine and other xenobiotics. TheNDUFB6 gene has been well-studied, and several transcript variants have been identified. One of these variants, NDUFB6 transcript variant 1, is of particular interest as a potential drug target or biomarker.

The NDUFB6 gene is a member of the NADH gene family, which is involved in the production of nicotine and other xenobiotics. The NADH gene family is composed of several subunits, including NDUFB1, NDUFB2, NDUFB3, NDUFB6, and NDUFB7. Each of these subunits has a distinct function in the production of nicotine and other xenobiotics.

NDUFB6 is a key enzyme in the metabolism of nicotine. In addition to its role in the production of nicotine, NDUFB6 is also involved in the metabolism of other xenobiotics, such as indole and 2-phenyl-1-propanone. These metabolites are potentially harmful, and NDUFB6 plays a crucial role in breaking them down into less toxic compounds.

The NDUFB6 gene has been well-studied, and several transcript variants have been identified. One of these variants is NDUFB6 transcript variant 1, which is of particular interest as a potential drug target or biomarker. This variant is expressed in the liver and has been shown to be involved in the metabolism of nicotine and other xenobiotics.

In addition to its role in the metabolism of nicotine and other xenobiotics, NDUFB6 transcript variant 1 is also involved in the regulation of gene expression. Studies have shown that this variant is involved in the negative regulation of gene expression, which is a mechanism by which the body's cells control the production of specific proteins.

The potential implications of NDUFB6 transcript variant 1 as a drug target or biomarker are significant. The production of nicotine and other xenobiotics is a potentially harmful process, and NDUFB6 plays a crucial role in the metabolism of these substances. By targeting this enzyme, potential drugs could be developed to treat nicotine addiction and other xenobiotics-related disorders.

In addition to its potential as a drug target, NDUFB6 transcript variant 1 is also a potential biomarker for certain diseases. The metabolism of nicotine and other xenobiotics is altered in a variety of diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. By measuring the expression of NDUFB6 transcript variant 1, researchers could potentially identify new biomarkers for these diseases.

Overall, NDUFB6 transcript variant 1 is a promising candidate as a drug target or biomarker. Further research is needed to fully understand its functions and potential implications in the context of nicotine and other xenobiotics metabolism and disease.

Protein Name: NADH:ubiquinone Oxidoreductase Subunit B6

Functions: Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone

The "NDUFB6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NDUFB6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets